-->

Progress in Adult Acute Lymphoblastic Leukemia: More Treatment Options, Improved Outcomes

Released On
December 30, 2020

Expires On
February 26, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Practicing Clinicians Exchange.

This activity is supported by an educational grant from Servier Pharmaceuticals LLC.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)
  • Pharmacists — maximum of 1.0 contact hours (0.10 CEUs)
  • Nurses — 1.00 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Survival and cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly due to a number of factors: an enhanced understanding of molecular genetics and disease pathogenesis, the implementation of risk-adapted therapeutic strategies, the use of allogeneic hematopoietic stem cell transplantation, the development of targeted agents, and the incorporation of regimens typically used for children that may benefit adults. In this expert review, Daniel DeAngelo, MD, PhD discusses disease pathophysiology and epidemiology, as well as how to determine patients’ risk categories and identify initial therapy accordingly. He also provides practical advice on how to mitigate treatment-related adverse events and better educate patients about their disease and treatments to ensure better adherence and outcomes.

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify the symptoms, classification, and stages of initial treatment for ALL
  • Evaluate novel agents for ALL, including where they fit in the treatment paradigm and their potential benefits and risks
  • Implement strategies to more effectively educate patients on the treatment of ALL, including possible adverse events of novel treatments and how to address them

Faculty

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

 

Joint Accreditation Statement

In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

 

ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
Nurse planner: Natasha L. Johnson, MSN, APRN, AOCNP, Moffitt Cancer Center, Tampa, Florida

 

AAPA Credit Designation

Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 25, 2021. PAs should claim only credit commensurate with the extent of their participation.

 

PA planner: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois

 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Daniel J. DeAngelo, MD, PhD

  • Consultant: Amgen, Autolus Therapeutics, Celgene, Incyte, Jazz Pharmaceuticals, Pfizer, Shire, Takeda
  • Consultant/Grant Support: Blueprint Medicines, Novartis
  • Grant Support: AbbVie, Glycomimetics

Natasha L. Johnson, MSN, APRN, AOCNP has no relevant financial relationships to disclose.

Corinne Williams, PA-C

  • Consultant: AstraZeneca

None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose, except Ms Williams as noted above.

Instructions for Participation and Credit

Participants wishing to earn CE/CME credit must::

  1. Read the content in its entirety.
  2. Relate the content material to the learning objectives.
  3. Complete the post-test and evaluation form.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.

The estimated time to complete this activity is 1.00 hour.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.